Singapore Markets open in 3 hrs 42 mins
Straits Times Index
3,239.03 +26.39 (+0.82%) S&P 500
3,977.53 +6.54 (+0.16%) Dow
32,432.08 +194.55 (+0.60%) Nasdaq
11,768.84 -55.12 (-0.47%) BTC-USD
27,112.41 -735.76 (-2.64%) CMC Crypto 200
587.32 -20.14 (-3.32%)
AZN Jul 2023 75.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 12:31PM EDT. Market open.
| Previous close | 3.2500 |
| Open | 3.2500 |
| Bid | 2.7600 |
| Ask | 3.2500 |
| Strike | 75.00 |
| Expiry date | 2023-07-21 |
| Day's range | 3.2500 - 3.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 91 |
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
